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Abstract
Aim—To assess the impact of the 5-fluorouracil (5-FU) drug-pathway genes on cytotoxicity, and
determine whether loss-of-function analyses coupled with functional assays can help prioritize
pharmacogenomic candidate genes.
Materials & methods—Dose-response experiments were used to quantify the phenotype of
sensitivity to 5-FU following the specific knockdown of genes selected from the 5-FU PharmGKB
drug pathway in three human colorectal cell lines. Changes in sensitivity were considered
significant if the IC50 for shRNA-exposed cells were three standard deviations outside the mean
IC50 for control-treated cells.
Results—Of the 24 genes analyzed, 13 produced significant changes on the phenotype of
sensitivity to 5-FU (DHFR, DPYS, DTYMK, DUT, FPGS, GGH, NME1, NT5C, RRM1, TYMS,
UCK2, UNG and UMPS).
Conclusion—The RNAi screening strategy enabled prioritization of the genes from the 5-FU
drug pathway. Further validation of the genes credentialed in this study should include gene
activity or expression and mutation analyses of clinical samples.
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5-fluorouracil (5-FU) is widely used in the therapy of solid tumors, including colorectal,
breast, head and neck cancers. The clinical efficacy of 5-FU can be improved significantly
by associating 5-FU with biochemical modulators such as folinic acid (leucovorin), used in
combination with synergic drugs such as oxaliplatin and irinotecan [1,2], or by the addition
of monoclonal antibodies directed against VEGF or EGF receptor [3-5]. Toxicity remains a
major limitation in the clinical efficacy of 5-FU. Although 5-FU was developed
approximately 50 years ago, based on the concept that it would kill cancer cells by acting as
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a competitive antagonist of uracil, many aspects of its mechanism of action remain to been
fully characterized [6]. 5-FU is regulated via a complex network of anabolic and catabolic
genes (Figure 1). 5-FU is inactivated by catabolism into fluorinated β-alanine [7] via the
sequential activities of gene products from dihydropyrimidine dehydrogenase (DPYD),
dihydropyrimidinase (DPYS) and ureidopropionase β (UPB1). Patients with congenital
deficiency in DPYD can experience 5-FU side effects, including severe myelo-suppression,
cardiac toxicity, mucositis and hand–foot syndrome owing to prolonged exposure to the
drug [8]. The prevalence of DPYD partial deficiency in the general population is
approximately 5% and total deficiency is rare at approximately 0.2% [9-11]. Partial or
complete DPYD deficiency is linked to genetic modifications, including SNPs, [11], deletion
mutations [12,13] and methylation [14]. 5-FU catabolism can also be impaired by genetic
alterations in DPYS [15,16] or UPB1 [17-19].
Early biochemical studies demonstrated that 5-FU could be metabolized through complex
anabolic pathways into several active metabolites that kill cells by disrupting DNA or RNA
synthesis or by inhibiting the enzymes required in pyrimidine synthesis (Figure 1) [20]. The
5-FU metabolite 5-fluoro-2′-deoxyuridine (FdUMP) inhibits the activity of thymidylate
synthase (TYMS) by forming a covalent ternary complex involving FdUMP, TYMS and
5,10-methylenetetrahydrofolate. Since cells rely on thymidylate synthase activity for de
novo DNA synthesis and repair, thymidylate synthase inhibition by FdUMP is believed to be
the main mechanism by which 5-FU exerts its cytotoxic, and by extension, therapeutic
effects [1]. FdUMP is formed as a result of the activities of the gene products of thymidine
phosphorylase (TYMP or ECGF1) and thymidine kinase 1. 5-FU can also be converted into
5-fluorouridine monophosphate (FUMP) via a direct mechanism involving orotate
phosphoribosyl transferase (OPRT; gene product of uridine monophosphate synthase
[UMPS]) or indirectly by the actions of uridine phosphorylase 1 and uridine kinase (UCK2).
FUMP is the precursor for the formation of two other cytotoxic metabolites: deoxyuridine
triphosphate (dUTP) and 5-fluorouridine triphosphate. The metabolite dUTP is cytotoxic
after its misincorporation into DNA where it causes irreparable DNA damage during
synthesis and repair. 5-fluorouridine triphosphate misincorporation into different RNA
structures kill cells by disrupting their cellular metabolism and homeostasis [21,22].
Most studies of 5-FU resistance have focused on TYMS. Overexpression of TYMS mRNA
and its protein is linked to resistance to 5-FU, both in vitro and in vivo [23,24]. Genetic
alterations leading to modifications in TYMS include polymorphisms in the TYMS promoter
region [25] and copy number variation [26]. In addition to TYMS expression, increased
expression in tumor cells of other enzymes from the 5-FU metabolic pathway such as DPYD
[27,28], or thymidine phosphorylase [29] have been correlated with resistance to 5-FU.
Studies investigating the role of tumor suppressor p53 in modulating the response to 5-FU is
contradictory at best. While in vitro studies demonstrated that loss of p53 confers cell
resistance to 5-FU [30], another study demonstrated that increased p53 expression in tumor
tissue correlated with 5-FU resistance [31]. Yet another study suggested that p53 had no
predictive value in the outcome of 5-FU-based therapy [32].
Given the many potential regulators of 5-FU activity, we performed a large-scale
credentialing study of 5-FU pathway genes across multiple human colorectal cancer cell
lines to provide quantitative data on key candidates for individualized therapy studies.
Materials & methods
Cell lines
Colorectal cell lines HCT-116, SW620 and HT-29 were acquired from American Type
Culture Collection (ATCC, VA, USA). HCT-116 cells were cultured in McCoy’s 5A
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medium (Cellgro, VA, USA) containing 0.075% sodium bicarbonate (Cellgro). SW620 and
HT-29 cells were cultured in RPMI 1640 and DMEM, respectively (both purchased from
Gibco, CA, USA). All cell culture media were supplemented with 10% fetal bovine serum
(Sigma, MO, USA) and 100 U/ml penicillin and streptomycin (Cellgro). Cell cultures were
incubated at 37°C and 5% CO2 in a humidified atmosphere.
Plasmid shRNA
The OpenBiosystems (AL, USA) plasmid shRNA bacterial glycerol stocks were obtained
through the University of North Carolina at Chapel Hill (NC, USA) Lenti-shRNA Core. To
ensure that changes in phenotype were mediated by RNAi and not owing to off-target
effects, each gene in the library was represented by four–five distinct shRNA plasmids. For
hit selection, the phenotype had to be produced by at least two plasmids [33,34]. A plasmid
expressing the shRNA directed against the gene enhanced Green Fluorescence Protein
(eGFP; a nonmammalian gene) was used as a negative control. The plasmids were isolated
using the Macherey-Nagel (PA, USA) NucleoSpin Robot-96 plasmid kit. Briefly, bacteria
were inoculated in Terrific Broth medium (MP Biomedicals, OH, USA) containing 100 μg/
ml of Carbenicillin (Invitrogen, CA, USA) utilizing 96-well MN Square-well Blocks, grown
in a GeneMachines HiGro rotative incubator (CA, USA).
Transfection procedure
Exponentially growing colorectal cell lines (passages 5–15) were seeded at a density of
20,000 cells per well in 96-well plates and incubated overnight as described above. The
following day, media was aspirated and replaced with 50 μl of warm fresh complete media.
Cells were transfected with plasmid-liposome complexes composed of 100 ng plasmid
shRNA and 0.5 μg Lipofectamine 2000 (Invitrogen) in a final volume of 50 μl Opti-MEM®
I (Invitrogen). A total of 18 h following transfection, media was aspirated and cells were
dissociated by incubation with 0.05% trypsin-53mM EDTA in Hank’s Balanced Salt
Solution (HBSS; Cellgro). Transfectants were seeded in 384-well plates at a density of 1000
cells/well (32 wells/transfectant) and incubated for an additional 24 h. Liquid dispensing to
the 384-well plates was performed using a Tecan Freedom EVO® liquid dispenser (Tecan,
Männedorf, Switzerland).
Verification of RNAi effects on the phenotypes of sensitivity to 5-FU
To determine if the modifications observed in the phenotypes of sensitivity to 5-FU resulted
from the combined effects of specific gene knockdown in each one of the three colorectal
cell lines and 5-FU, we determined mRNA levels for the selected genes by quantitative real-
time PCR (qPCR). Individual transfections with two–three of the most effective shRNAs/
genes were performed as described above. A total of 48 h following transfection, total RNA
was isolated using the Trizol method (Invitrogen). A total of 300 ng of total RNA was
reverse transcribed with the Moloney murine leukemia virus reverse transcriptase (M-
MLUV; NE Biolabs, MA, USA) according to manufacturer’s instructions. Prevalidated
primers for qPCR were purchased from RealTimePrimers.com (Elkins Park, PA, USA,
Supplementary Table 1; see www.futuremedicine.com/doi/suppl/10.2217/pgs.10.188) [101].
Real-time PCR reactions were carried out in 384 well MicroAmp® Optical 384-Well
Reaction Plates (Applied Biosystems [ABI], CA, USA) and run as triplicates on a 7900HT
thermocycler (ABI). The reaction conditions were 95°C for 10 min, followed by 40 cycles at
95°C (15 s) and 58°C (1 min) in 15 μl reaction mixture composed of 7.5 μl of SYBR®
Green PCR Master Mix (ABI), 0.1 μM of both primers and 15 ng of cDNA. For the analysis
of qPCR data, the cycle thresholds (Ct) were normalized with RPLP0 [35] and baseline
expression levels were the normalized Cts from eGFP-shRNA transfectants. Relative
expression levels of target mRNA following shRNA transfection were calculated as
percentage of remaining mRNA levels with the expression ‘ΔΔCt × 100’ [36].
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Transfectants from each shRNA were treated with vehicle (media) or 5-FU over seven log
concentrations from 0.001–1000 μM (four replicates at each dose). A total of 96 h later,
AlamarBlue (Invitrogen) was added (10% final concentration); 6–8 h later fluorescence
values were acquired using the Tecan 1000 Multiplate Reader (Tecan). The fluorescence
readings were corrected for the blank before being converted into percentage cell survival at
each drug concentration and IC50 was determined from the dose-response curves utilizing
XLfit4.0 software from IDBS (IDBS, Guildford, UK). Figure 2 is an example of
representative phenotypes in the screen. The Z’-factors were greater than 0.7, therefore this
system was considered suitable for analyzing the impact of gene knockdown in cell
sensitivity to 5-FU [37].
Statistical methods
A plasmid shRNA was considered as ‘active’ when the resulting IC50 was shifted at least
three standard deviations from that found with the control shRNA-plasmid eGFP. In a given
cell line, a gene with two or more plasmids producing the same phenotype was considered
‘active’. A gene was selected as ‘credentialed’ in the 5-FU pathway when its knockdown
significantly altered IC50 in the HCT-116 cells (p53 wild-type) and at least one of the two
cell lines with mutated p53 (SW620 or HT-29 cells) and demonstrated a mean percentage of
remaining mRNA ± standard deviation of 40% or less as determined by qPCR.
Results
Loss of function analyses identify 13 genes involved in the modulation of 5-FU cytotoxicity
Of the 24 5-FU PharmGKB [102] drug pathway genes analyzed, knockdown of 13 of them
produced a significant change in cytotoxicity (Figures 2 & 3). A total of 12 of these genes
increased sensitivity to 5-FU cytotoxicity 3–12-fold, and only one gene, UMPS, increased
resistance by approximately twofold (Figure 4).
Confirmation of gene knockdown by qPCR
A total of 48 h after transfection with shRNA plasmids, mRNA levels for the selected genes
were measured by qPCR to confirm gene knockdown. For all three cell lines, mRNA levels
were consistently diminished to 10–40% of control levels (Figure 5), indicating that the
observed phenotypes were associated with specific gene knockdown.
Conversion of 5-FU into FUMP plays a major role in the cytotoxic effects of 5-FU
The knockdown of UMPS gene resulted in a significant shift in the IC50 (Figures 2 & 3), and
a approximately twofold increase in cell resistance to 5-FU in both HCT-116 and SW620
cell lines (Figure 4), demonstrating that UMPS, the gene responsible for the conversion of 5-
FU into FUMP, is a relevant gene in the 5-FU pathway. The knockdown of UCK2 and
NT5C, genes also involved in FUMP synthesis from 5-FU, resulted in a significant decrease
of the IC50 of a magnitude of 3- to 6-fold in all three cell lines. NME1, UNG and RRM1
produced a significant shift in the IC50 (a decrease of 4- to 13-fold) in all three cell lines
(Figures 3 & 4), indicating that NME1, UNG and RRM1 may be mediators of 5-FU drug
pathway.
Knockdown of genes involved in thymidine biosynthesis sensitizes cells to 5-FU
The knockdown of the TYMS gene resulted in a 3–8-fold enhancement of the cytotoxic
effects of 5-FU in all three cell lines. Two additional genes involved in thymidine synthesis
also produced a significant decrease in IC50 following knockdown: DTYMK (threefold
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decrease in HT-29 cell lines and approximately fivefold decrease in HCT-116 cells) and
DUT with 13- and three-fold reduction, respectively, in HCT-116 and SW620 cells.
Disturbance of folate homeostasis increases the cytotoxic effects of 5-FU
Knockdown of two genes involved in the homeostasis of folates, namely DHFR and GGH,
produced a significant decrease of the IC50 in all three cell lines (3–10-fold), whereas
reduced activity of FPGS resulted in a significant decrease in the IC50 by three- and six-fold
in HCT-116 and HT-29 cell lines, respectively (Figure 4).
Apoptosis-related genes from the 5-FU pathway do not influence sensitivity
5-fluorouracil is known to induce apoptosis in human cancer cells. However, the candidate
apoptosis genes from the 5-FU PharmGKB pathway (FDXR, TP53, FASLG and NFKB1) did
not demonstrate a significant change in sensitivity to 5-FU following specific knockdown
(Figure 3), suggesting that other genes might modulate cell death by apoptosis induced by 5-
FU in these cell lines.
Modulation of 5-FU catabolic pathway by DPYD
The DPYD gene knockdown did not significantly modify the phenotype of sensitivity to 5-
FU in HCT-116 and HT-29 cell lines (Figure 3), whereas the depletion of DPYS gene-
activity resulted in a significant reinforcement of 5-FU-induced cytotoxicity in all three cells
lines (fold change of the IC50 ranged from approximately 3–7, Figure 4). UPB1 gene
knockdown produced a significant increase in the IC50 in the SW620 and HT-29 cell lines
(both with mutated p53), but not in the HCT-116 cells (with wild-type p53, Figure 3).
Therefore, amongst the three genes of the 5-FU catabolic pathway, in this platform, only
DPYS was credentialed as a modulator of the 5-FU pathway.
Discussion
Variability in patient response to drug therapy is a major hurdle in the delivery of optimal
efficacy in anticancer chemotherapy. The PharmGKB drug pathway effort is an important
tool for conceptualizing sources of variability of therapy outcome. The ability to identify
those genes within a drug pathway most likely to modulate therapeutic outcome is
paramount in establishing individualized therapy.
We exploited the flexibility of a platform of RNAi reagents and a cell panel of three
colorectal cell lines to determine the roles of 24 genes from the PharmGKB pathway in the
phenotype of sensitivity to 5-FU. We were able to identify 13 genes as modulators of the 5-
FU drug pathway (Figure 6A). The mRNA levels of the genes we analyzed were reduced by
more than 60%, as determined by qPCR. Thus, the RNAi screening strategy we used is a
useful tool for prioritization of the genes from the 5-FU drug pathway. Interestingly, seven
of the genes we validated (DHFR, FPGS, GGH, NME1, UCK2, UMPS and UNG) were
previously found to be differentially expressed between tumor samples and its adjacent
normal tissue in 52 patients with Dukes C colorectal cancer [38]. Therefore, the in vitro
system we developed may be useful in predicting experimentally, which pharmacogenomic
genes are most likely to be cancer drug biomarkers.
The gene product of UMPS is the enzyme OPRT, which converts 5-FU into FUMP, a
common substrate for the production of 5-fluorouridine triphosphate and dUTP, two
cytotoxic metabolites that target RNA and DNA, respectively. Our data demonstrated that in
the 5-FU anabolic pathway UMPS was the only gene that produces a cellular phenotype of
5-FU resistance, suggesting that in this cellular system, the misincorporation of 5-FU
metabolites into RNA and DNA are important in the initiation of 5-FU cytotoxicity (Figure
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6B). Furthermore, there is some evidence to suggest that an increase of UMPS mRNA
expression is observed in tumor tissue when compared with adjacent normal tissue
[7,38,39]. In addition, high OPRT activity or increased UMPS mRNA expression are
associated with greater survival [39,40], suggesting that UMPS may play roles of clinical
relevance in 5-FU-based chemotherapy regimens.
Although TYMS is considered an important molecular target of 5-FU [1,41], our results
demonstrated that ten additional genes of the 5-FU anabolic pathway (DHFR, DTYMK,
DUT, FPGS, GGH, NME1, NT5C, RRM1, UCK2 and UNG), produced a phenotype of cell
sensitization to 5-FU following knockdown. The disruption of the activity of TYMS or
DHFR, GGH, DUT, DTYMK and FPGS interferes with thymidine synthesis (Figure 6B),
whereas the knockdown of NME1, RRM1, UCK2 and UNG, all genes acting downstream of
UMPS, affect cell viability by interfering with RNA or DNA synthesis (Figure 6B). Thus,
the cytotoxic effects of 5-FU might be under the regulation of complex mechanisms,
implicating not only TYMS, but at least these ten other genes credentialated in this study.
The knockdown of DPYS produced a robust phenotype of sensitization in all three cell lines,
indicating that changes in DPYS gene-activity may be influential in 5-FU clearance. Since
congenital DPYS deficiencies do not always cause clinical abnormities [15], our results
suggest that DPYS should be considered for future studies aimed at understanding the
mechanisms of 5-FU toxicity. The knockdown of DPYD, a gene with a well established role
in fluoropyrimydine toxicity [8], did not result in significant changes in cell sensitivity,
which may reflect a limitation in our screening panel in capturing all modulators. Mutations
in UPB1 can affect patients’ response to 5-FU therapy [17], and our results suggest that
UPB1 may influence 5-FU catabolism when p53 is mutated. Taken as a whole, our
observations indicate that DPYS and UPB1 should also be considered more carefully in the
study of 5-FU toxicity.
We have developed an in vitro platform for the credentialing of pharmacogenomic candidate
genes identified from known drug pathways. This system can also be applied in the analyses
of genes from chromosomal regions identified through whole-genome studies or other
discovery approaches [42]. This approach can be expanded to different cell types, larger
number of cell lines per tumor type, or other ways that maximize its utility in future
pharmacogenomic studies. The data generated by this approach can be used to create
dynamic drug pathways that reflect the relative impact of a gene on a given drug therapy.
This information will then be useful to prioritize gene-variant discovery and focus studies on
modulating chemotherapeutic response. Studies on the genes prevalidated in vitro could then
be further investigated in order to determine the genetic modifications with the potential to
impact in the clinic, for example, via SNP analyses (Supplementary Table 2; see
www.future-medicine.com/doi/suppl/10.2217/pgs.10.188) or gene copy number variation.
The findings from these studies should impact tremendously on the reduction of the scope of
genes to be considered in future pharmacogenomic clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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▪ The phenotype of sensitivity to drugs may be modulated by some of the
genes from the 5-fluorouracil (5-FU) drug pathway.
▪ RNAi strategy was used to prioritize genes from the 5-FU pathway.
▪ Our findings suggests that UMPS can be one of the major regulators of the
cytotoxic effects of 5-FU.
▪ In addition to TYMS this study demonstrate that other genes from the 5-FU
metabolic pathway (DHFR, DTYMK, DUT, FPGS, GGH, NME1, NT5C,
RRM1, UCK2 and UNG) may be involved in the cytotoxic effects of 5-FU.
▪ This RNAi screening platform can capture most, but not all of the drug-
pathway gene regulators.
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Figure 1. PharmGKB 5-fluorouracil drug pathway
Enzyme names are shown in yellow oval circles, and their interacting metabolites are
represented in blue octagonal circles.
Adapted with permission from [102].
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Figure 2. Dose-response plots for 5-fluorouracil; in HCT-116 cells transfected with control
shRNA Green Fluorescence Protein (diamonds), uridine monophosphate synthase shRNA
(squares) and dihydropyrimidine dehydrogenase shRNA (circles)
Each data point is the mean percentage survival ± standard deviation for four replicates at
each drug concentration.
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Figure 3. Phenotypes of sensitivity of the genes from the 5-fluorouracil pathway following gene
knockdown in colorectal cell lines
Profiles of sensitivity to 5-fluorouracil in each cell line were determined according to mean
IC50 values for 2–3 shRNAs producing the same phenotype. Phenotype of sensitivity (dark
blue boxes; mean IC50 ≤ mean IC50 control -3 standard deviation [SD]), resistance (light
blue boxes; mean IC50 ≥ mean IC50 control +3 SD normal sensitivity (white boxes; mean
IC50 within the range mean IC50 control ±3 SD).
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Figure 4. Profiles of cell sensitivity of PharmGKB genes ordered by HCT-116 response
Waterfall diagrams show fold change in the IC50 relative to control of each gene. Positive
values represent fold change in IC50 ≥ 1 or more, and negative values represent fold change
in IC50 of less than 1. Cell lines utilized were (A) HCT-116; (B) HT-29; and (C) SW620.
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Figure 5. mRNA levels of target genes following shRNA knockdown
The histograms show the reduction in mRNA levels for the target genes 48 h following
knockdown with shRNA plasmids in (A) HCT-116, (B) HT-29 and (C) SW620 colorectal
cell lines. For each gene, data was expressed as mean ± standard deviation for the selected
2–3 shRNAs.
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Figure 6. 5-fluorouracil functional drug pathway reflecting the relative impact of each gene
(A) Phenotypes were: moderate sensitivity (orange, mean fold change of IC50 for active
genes of 5 or less), strongly sensitive (red, mean fold change of IC50 for active genes >5),
resistant (green, mean fold change of IC50 for active genes >2) and normal (yellow, no
significant change in IC50). (B) Modified 5-fluorouracil drug pathway highlighting the gene
modulators prioritized by RNAi strategy.
Adapted with permission from [102].
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